Like Kleenex and Band-Aid, Botox® is a brand name that’s become indistinguishable from the product. But in a new randomized study, Botox®’s newer competitor, Dysport®, appeared to have the edge in smoothing wrinkles.
Botox® (onabotulinumtoxinA) was approved by the Food and Drug
Administration (FDA) to treat frown lines — those pesky wrinkles between
the eyebrows — in 2002. In 2009, a competitor, Dysport®
(abobotulinumtoxinA) was approved for the same use.
Both drugs have also been approved for other cosmetic and medical
uses, and doctors administer them widely to smooth wrinkles even in
areas they haven’t been specifically approved to treat, namely around
the outer corner of the eyes.
The new study aimed to figure out which product worked better to
improve the appearance of such creases, known as crow’s feet — the
wrinkles that fan out when you smile, laugh or squint. Researchers from
the Maas Clinic in San Francisco and University of California, San
Francisco, enrolled 90 people for a “split face” study in which doctors
randomly injected Botox® into one side of the face and Dysport® into the
Using a five-point scale, the researchers then evaluated results on
both sides of the participants’ faces; the patients themselves were also
asked to indicate which side they preferred. According to the
researchers’ measure, Dysport® improved the appearance of crow’s feet
significantly better than Botox® did. At the 30-day mark, about
two-thirds of participants said they also favored the side that had been
treated with Dysport®. But the difference was seen only when users
contracted their facial muscles as much as possible. There was no
difference in appearance when faces were at rest.
The authors, who published their findings Monday in the Archives of Facial Plastic Surgery, said
that additional research would be necessary to determine whether
Dysport® would prove more effective in other areas of the face and why
the two drugs might work differently.
MORE: Pretty Boys: Plastic Surgery Isn’t Just for Women Anymore
A caveat: the makers of both Botox® and Dysport® — Allergan Inc. and
Medicis Aesthetics, respectively — were asked to help fund the study,
but only Medicis paid for the research.